RecruitingObesity
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Eligible age
18+ yrs
Accepts
All genders
Locations
19 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
Sponsor: Kailera
Where it's recruiting
Source: ClinicalTrials.gov · NCT07284979 · last updated 2026-06-18